Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

NCT05926427 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

CNS Lymphoma

Interventions

DRUG: Orelabrutinib
DRUG: Rituximab
DRUG: Chemotherapy

Sponsor

Ruijin Hospital